TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia

Ibrutinib may revert the T-helper (Th)2 polarization observed in chronic lymphocytic leukemia (CLL) by targeting the IL-2-inducible kinase, that shows a significant homology with the Bruton tyrosine kinase. In the front-line GIMEMA LLC1114 trial (ibrutinib+rituximab for 6 months, followed by ibrutin...

Descripción completa

Detalles Bibliográficos
Autores principales: Puzzolo, Maria Cristina, Del Giudice, Ilaria, Peragine, Nadia, Mariglia, Paola, De Propris, Maria Stefania, Cappelli, Luca Vincenzo, Trentin, Livio, Reda, Gianluigi, Cuneo, Antonio, Molica, Stefano, Piciocchi, Alfonso, Arena, Valentina, Mauro, Francesca Romana, Guarini, Anna, Foà, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082026/
https://www.ncbi.nlm.nih.gov/pubmed/33937038
http://dx.doi.org/10.3389/fonc.2021.637186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082026/
https://www.ncbi.nlm.nih.gov/pubmed/33937038
http://dx.doi.org/10.3389/fonc.2021.637186

Ejemplares similares